高雄市生物科技發展協會|http://www.khba.org.tw
會員登入
記住帳號 自動登入
會員名錄
各式辦法
下載專區
留言板
您目前的位置:首頁 / 活動與新訊
Gut microbiome plays a role in immune response to mRNA COVID vaccines
活動日期:2024.01.23
2024.01.23  

Gut microbiome plays a role in immune response to mRNA COVID vaccines

https://reurl.cc/v0anlk

Jan 4 2024Karolinska Institutet

Researchers from Karolinska Institutet in Sweden have discovered that the gut microbiome can influence how well people respond to mRNA COVID vaccines. The study, published in the journal npj Biofilms and Microbiomes, suggests that certain bacteria in the gut can enhance the immune response to the vaccine, whereas other bacteria may weaken it.

The gut microbiome is the collection of microorganisms that live in our digestive tract. It plays an important role in many aspects of our health, such as digestion, metabolism, and immunity. The researchers wanted to find out if the gut microbiome also affects the response to mRNA COVID vaccines. To do this, the researchers collected stool samples from 68 people living with HIV and 75 healthy individuals before their first mRNA COVID vaccine dose.

The researchers analysed the microbiome composition using a technique called 16S rRNA sequencing, which identifies the types and relative abundance of bacteria in the samples. They also measured the levels of antibodies and immune cells that were produced after the vaccination.

We correlated the microbial composition with immune responses and patient characteristics. This comprehensive analysis included age, gender, body mass index and clinical factors for people living with HIV, aiming to understand the complex relationship between gut microbes and vaccine efficacy."

Piotr Nowak, principal investigator, senior physician and associate professor at Karolinska Institutet's Department of Medicine, Huddinge

The results showed that the initial makeup of the gut microbiome could predict the immune response to the vaccine in both groups. They found that a less diverse gut microbiome was associated with a stronger vaccine response, marked by higher levels of spike protein antibodies and spike specific CD4 T-cells. These are key components of the immune system that help to neutralize the virus and prevent severe infection.

The researchers also identified specific bacteria that were linked with better or worse vaccine responses. For example, they found that Lactobacillus, Bacteroides, and Lachnospira were associated with higher antibody and immune cell levels, while Cloacibacillus was associated with lower antibody levels. They also found that Bifidobacterium and Faecalibacterium were microbial markers of individuals with higher antibody levels.

Omics eBook Compilation of the top interviews, articles, and news in the last year.Download the latest edition

According to the researchers, the study highlights the significant role of the gut microbiome in the effectiveness of mRNA COVID vaccines. The findings could lead to developing microbiota-focused treatments to enhance vaccine responses, especially in groups that may have weaker responses, such as the elderly or immunocompromised individuals. The potential strategies could include changing the diet or taking probiotics to improve the gut microbiome and immunity, the researchers suggest.

The study was conducted in collaboration with the Karolinska University Hospital, and SciLifeLab National Genomics Infrastructure in Stockholm, Sweden. The research was funded by Region Stockholm, the Swedish Research Council, and Physicians Against AIDS.

Source:

Karolinska Institutet

Journal reference:

Ray, S., et al. (2023). Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV. npj Biofilms and Microbiomesdoi.org/10.1038/s41522-023-00461-w.

共有314筆資料 頁數: 第13頁(共16頁)
編號 標題 新增日期
1 台灣疫苗產業政策及發展現況 研討會 2008.08.25
2 機電醫療器材研討會–從產品研發到上市法規 2008.09.03
3 「蛋白質藥物修飾技術發展趨勢」研討會 2008.08.20
4 「腫瘤藥物劑型技術發展趨勢與策略」研討會 2008.08.15
5 2008 生技暨醫療器材專利與技術商談會 2008.08.10
6 基因轉殖及複製與產業發展 2008.08.07
7 癌症疫苗治療之未來展望研討會 2008.08.01
8 細胞生物醫學影像新知國際研討(習)會 2008.07.24
9 從實務面來探討分子基因檢驗現況 2008.07.26
10 Bio Taiwan 2008 第六屆台灣生技月 2008.07.21
11 Bio Taiwan 2008 第六屆台灣生技月生技展-研討會議程 2008.07.18
12 2008國內學名藥市場現況分析及發展研討會 2008.07.04
13 劉院長:發展高雄為經貿及知識經濟為主的城市 2008.07.14
14 2008經濟部技術處科專優良成果表揚 2008.07.05
15 2008台北生技獎總獎金500萬,邀請您一起來挑戰 2008.07.01
16 藥事論壇講座(第二十九屆) 『生技醫藥研發成果篩選評估暨商化』 2008.07.01
17 2008首屆生技醫療星光大道醫療器材中小企業 明日之星選拔賽 2008.06.30
18 高雄市政府「地方產業創新研發推動計畫」(地方型SBIR)計畫說明會 2008.06.26
19 「生技新藥產業發展條例」與施行辦法說明會 南部場 (2008/6/17) 2008.06.06
20 97年度「貿易救濟爭端解決案例南區講習會」 2008.05.27
上一頁  1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16  下一頁
版權所有©2006 高雄市生物科技發展協會 所有文字、資料禁止轉用
地址:高雄市中正一路120號14樓之3 TEL:(07)591-9569 / FAX:(07)591-9018 / e-mail: khba.tw@gmail.com
累積進站人數:3123277